drugset
drugset / Trial / NCT05518578

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

NCT05518578 ↗

Phase 2 Recruiting 60 enrolled Supernus Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures

Timeline

Start
2023-02-07
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SPN-817 Unknown 4 mg Oral

Indications

epilepsy